SCIENTIFIC REPORTS

Received: 12 July 2017 Accepted: 12 June 2018 Published online: 17 August 2018

OPEN Characterization of the β -defensin genes in giant panda

Zhi-Yi Zhang¹, He-Min Zhang², De-Sheng Li², Tie-Yi Xiong³ & Sheng-Guo Fang¹

β-Defensins are small antimicrobial proteins expressed in various organisms and have great potential for improving animal health and selective breeding programs. Giant pandas have a distinctive lineage in Carnivora, and it is unclear whether β-defensin genes have experienced different selective pressures during giant panda evolution. We therefore characterized the giant panda (Ailuropoda melanoleuca) β -defensin gene family through gap filling, TBLASTN, and HMM searches. Among 36 β -defensins identified, gastrointestinal disease may induce the expression of the DEFB1 and DEFB139 genes in the digestive system. Moreover, for DEFB139, a significant positive selection different from that of its homologs was revealed through branch model comparisons. A Pro-to-Arg mutation in the giant panda DEFB139 mature peptide may have enhanced the peptide's antimicrobial potency by increasing its stability, isoelectric point, surface charge and surface hydrophobicity, and by stabilizing its second β -sheet. Broth microdilution tests showed that the increase in net charge caused by the Pro-to-Arg mutation has enhanced the peptide's potency against Staphylococcus aureus, although the increase was minor. We expect that additional gene function and expression studies of the giant panda DEFB139 gene could improve the existing conservation strategies for the giant panda.

Defensins are a group of small antimicrobial peptides (AMPs) found in large variety of plants, invertebrates, and vertebrates that act against a broad spectrum of pathogens including enveloped viruses, gram-positive and gram-negative bacteria, mycobacteria, and fungi¹. There are three defensin subfamilies known as α , β , and θ defensins; among these, β -defensins represent the oldest family, and most mammalian β -defensins arose before the last common ancestor of eutherian mammals $^{1-4}$. β -defensin proteins are expressed mainly by mucosal epithelial cells lining the respiratory, gastrointestinal, and genitourinary tracts, but the expression pattern and antimicrobial properties of many β -defensins remain unknown^{1,4}.

Apart from killing microbes directly, recent studies have discovered novel roles for β -defensins in immunology and reproduction. Navid *et al.* (2012) found that mouse β -defensin 14 (Defb14) can mediate the immune response by regulating T cells⁵. Human DEFB2, DEFB3, and their mouse orthologs are also chemoattractants used for recruiting immune cells to fight against infection⁶. Hardwick et al. (2011) found higher DEFB103 expression levels in the epithelial cells of people from East Asia⁷, which can increase influenza resistance in this population. In macaques, spermatozoa coated with DEFB126 are protected from attack by the female immune system, which facilitates fertilization^{8,9}. Furthermore, certain variants of some β -defensins in human and cattle are also related to fertility^{8,10}. Because of these properties, several potential applications for β -defensins can be envisioned for improving animal health, including the design of antibiotics that would avoid the emergence of resistance, the development of vaccine adjuvants, dietary manipulations that enhances gut disease resistance, and selective breeding for breeds with higher fitness^{1,11,12}.

Giant pandas represent the 'national treasure' of China and a flagship for world wildlife conservation. These animals have received much attention not only because of their endangered status, but also because of their intriguing evolutionary history. To date, many genetic analyses have investigated the phylogeny, genetic variation, population history, adaptive evolution, and structure of this species using a combination of molecular markers including fingerprint probes, microsatellites, mitochondrial DNA, and major histocompatibility complex (MHC) loci¹³. As one of the most important disease resistance genes, MHCs in the giant panda are extensively studied to

¹The Key Laboratory of Conservation Biology for Endangered Wildlife of the Ministry of Education, and State Conservation Centre for Gene Resources of Endangered Wildlife, College of Life Sciences, Zhejiang University, Hangzhou, 310058, P. R. China. ²China Research and Conservation Center for the Giant Panda, Wolong, 623000, P. R. China. ³Emeishan Biological Resources Research Station, Sichuan Provincial Academy of Natural Resources Sciences, Chengdu, 610015, P. R. China. Correspondence and requests for materials should be addressed to S.-G.F. (email: sgfanglab@zju.edu.cn)

	Signal	peptide	Pro-piece
Aimo DEER SDAG11	I≪	KVI ELEMIEC	
Aime DEFB_SPAGII	n	DC ICIETCIII	
Aimo DEER1	ORHERI GKRI SARDREEDI CI HRASRAODA	ACROERT CELLT CV	
Alme-DEPB1	.QKH3KLGKFL3AKFFEEFLCLHKA3KAQFA	ASKFERISFEEL.GVEF	
Aime DEFB105	1	TIER ME VEVIAE ET	
Aime DEFB12	1	-TLSK.HSTEVLAP.FIL	AD DN
Aime-DEFB 105	•	KIF	
Aime-DEFB107		SISAALILU	LVH1F5.KG
Aime-DEFB108	EPS	SFLESAA.RPAA.LLTILFC	NSVCP
A1me-DEFB 109		KLHV.L-FMLLFS	S1F. SPVRS
Aime-DEFB 110		IHLF.FI.LFWV	VTI.PAKKKYPQ
Aime-DEFB112		NLS.SI.SFG	VFISPARSKEQYA
Aime-DEFB 113		KI.CIFL	LTFVFTVSCGPSVSQKKT
Aime-DEFB114		YCLLHFL.YV	VTFILP.TC
Aime-DEFB116		SVM.PYLMTISILLI	LVRKTPGGL-FRSQY-
Aime-DEFB116-like		PYLMTI.ILLI	LVHKTSG
Aime-DEFB117		F.ILTLIVFLILFQ	MQPVCG
Aime-DEFB119		FL.ILLAM	MKPS
Aime-DEFB121		RLML.VLAVILLU	LVRVT
Aime-DEFB123		L.TLAALLLI	LSQ.TPGGT
Aime-DEFB 124		TQL.LI.ALLAL	LGH. PPGRS
Aime-DEFB125		NLM.TFIICGFU	LNLVT
Aime-DEFB126		SM.TLAS.MLI	LAQV.SG
Aime-DEFB 126-like		SLFTLTI.VLI	LAHSG
Aime-DEFB127		LLII.I.LFO	KSKVTE
Aime-DEFB128		LFLVLII.OFE	IPTDT
Aime-DEEB129		PTEASI (0Y0/WTFYEG
Aime-DEER 130	1	RIH SIS IF	WITTIDK RT
Aime-DEER 131	1	R HSTEGVI ALL	STVD RT
Aime-DEER 132	·	VEAS GEL	G G
Aimo DEFD 134			
Aimo DEED 134	1	E LEVA VIVAL	
Alme-DEPB135	1	CFVE.VEVE	
Aime-DEFB 136		S.SGLLLI	LIS PSONG
Aime-DEFB 138		K LFLLLI	
Aime-DEFB 139		L.LIFVVLF	1581/0/20
Aime-DEFB 140		RL.HVALTAA.MVI	LQV. PJG1KA
Aime-DEFB 2		RIHCFI.PVLF	FLSPAPGFS
			Mature peptide
1			Mature peptide >>
Aime-DEFB_SPAG11	PGIRDVICLTQHGTCRLFFCHFG	GEKKAEICSNP-WNRC	Mature peptide >>
Aime-DEFB_SPAG11 Aime-DEFB_SPAG11B	I≪ PGIRDVICLTQHGTURLFFCHFG .ELDFKV.D.KKSEY QEYNYP	GEKKAEICSNP-WNRCC M.IQVGY.FKKK-YA.	Mature peptide ≫ LPTTEAEGKIK/PETDGKND
Aime-DEFB_SPAG11 Aime-DEFB_SPAG11B Aime-DEFB1	← PGIRDVICLTQHGTCRLFFOHFCC .ELDFKV.D.KKSEYQEYNYY F.Q.SDHYV.ARRGNFSPPLF	GEKKAEITSNP-WNRCT M.IQVGY FKKK-YA. FTRVDGT YGGK-AK.	Mature peptide LPTTEAEGKNKPETDGKND
Aime-DEFB_SPAG11 Aime-DEFB_SPAG11B Aime-DEFB1 Aime-DEFB103	≪ PGIRDVICLTQHGTORLFFOHFG .ELDFKV.D.KKSE,Y_QEYNYF F.Q.SDHYV.ARRGNFSP PLF IINTLQRYY_QIRGR_A.VS LPR	GEKKAEICSNP-WNRCT M.IQVGY FKKK-YA. FTRVDGT YGGK-AK. R.EQIGR .SGG-RK.	Hature peptide LPTTEAESKNYPETDGKND→ INN NR RKKK
Aime-DEFB_SPAG11 Aime-DEFB_SPAG11B Aime-DEFB1 Aime-DEFB183 Aime-DEFB183	PGIRDVIELTQHGTERLFFHFG .ELDFKV.D.KKSE,Y.QEYNYP F.Q.SDHYV.ARG, NFSPPL IINTLORYY QIGGR, K.SSPT G.EFAACEP RLSR,K.RM	GEKKAEIDSNP-WNRCK M.IQVGY FKKK-YA. FTRVDGT YGGK-AK. R.EQIGR .SGG-RK. DVVGN KMN-FF.	Mature peptide >> I IPTTEAESONDETDGEND
Aime-DEFB_SPAG11 Aime-DEFB_SPAG11B Aime-DEFB1 Aime-DEFB183 Aime-DEFB12 Aime-DEFB126	I PGIRDVIILTQHGTERLFFDFG PGIRDVIILTQHGTERLFFDFG PGIF F, Q.SDHYA ARGG, NFS-PSPFF PIIINTLQHYQ QRG, RFS-PSPFG G. EFAACEP RLSR, K., RMTEG FED	GEKKAEIDSNP-WNRCT M.IQVGY_FKKK-YA. FTRVDGT_YGGK-AK. R.EQIGR_SGG-RK D.VVGN_KMN-FF. N.ELVAL_QKSLK	Hature peptide LPTTEAEGKNKYPETDGKND IAQ NR RKK RKK RKK TLQPCNKSKDDNSEDSGFPERIK
Aime-DEFB_SPAG11 Aime-DEFB_SPAG11B Aime-DEFB103 Aime-DEFB103 Aime-DEFB102 Aime-DEFB106 Aime-DEFB107	I PGTRDVII LTQHGTTRLFFHFC ELDFKV.D KXSEN QEVNY F.Q.SDHYV ARRGNFSP PLF IINTLQRYY QIRG	GEKKAEITSNP-WNRCT M.IQVGY_FKKK-YA. FTRVDGT YGGK-AK. T.EQIGR .SGG-RK. D.VVGN_KMN-FF. N.ELVAL.QKS-LK. F.VIGG RAELTPF.	Mature peptide > I LPTEAEGKIMPETOGRND. > I Max > I REX > I REXIS > I TLQPCMSKDDNSEDSGFPERHK. > I KNNWK > I
Aime-DEFB_SPAG11 Aime-DEFB_SPAG11B Aime-DEFB1 Aime-DEFB183 Aime-DEFB12 Aime-DEFB126 Aime-DEFB106 Aime-DEFB107 Aime-DEFB188	Image: Point of the second s	GEKKAEICSNP-WNRCT M.IQVGY FKKK-YA. FTRVDGT YGGK-AK. R EQIGR .SGG-RK. D.,VVGN KMN-FF. N.ELVAL.QKS-LK. F.VIGG RAELTPF. S.LQGR L.G-QP.	Hature peptide LPTTEAEGKNKPETDGKND
Aime-DEFB_SPAG11 Aime-DEFB_SPAG118 Aime-DEFB 183 Aime-DEFB 183 Aime-DEFB 186 Aime-DEFB 187 Aime-DEFB 187 Aime-DEFB 188 Aime-DEFB 189	I ≪ DVII LTQHSTIRLFFHFC PGIRDVII LTQHSTIRLFFHFC ELDFKV. D KKSE, N QEYNY F, Q. SHYV ARGG, N A, VSS PL IINTLQNYV QIRG, N A, NSS PL GEPACEP RIS, N, A, NSS	GEKKAEICSNP-WNRCT M.IQVGY FKKK-YA. FTRVDGY FGK-AK. R.EQIGR .SGG-RK. D.,VVGN KKN-FF N.ELVAL QKS-LK. F.VIGG RAELTPF S.LQGR L.GQP. T.QQIGA RR-R-N.	Mature peptide >> I LTTEAEGKINKPETDGKND
Aime-DEFB_SPAG11 Aime-DEFB_SPAG118 Aime-DEFB 18 Aime-DEFB 18 Aime-DEFB 12 Aime-DEFB 12 Aime-DEFB 167 Aime-DEFB 168 Aime-DEFB 168 Aime-DEFB 168	EUFKV. D (KKSE // QEF HGT/RLFF HFF RELDFKV. D (KKSE // QEF MY F. Q. SDHYW ARRG N. NFSP D LP G. EFAACEP RLSR.K. MSS LPR G. EFAACEP RLSR.K. MSS LPR FED EC FK N. N. MSS RK GTHRENQ QRMD R EAE LS KAGRFKEV ERM M. VSS LS LASGENR, N LS LASGENR, N LS 	GEKKAEIT SNP-WNRT M.IQVGY FKKK-YA. FTRVDGT YGGK-AK R.EQIGR \SGG-RK D.VVGK KNN-FF N.ELVAL QKS-LK F.VIGR AELTPF. S.LQGR L.G-QP T DQIGR AR-R-N. S.IRIAF IR.G-TH	Hature peptide LPTTEAEGKNKPETDGKND
Aime-DEFB_SPAG11 Aime-DEFB_SPAG118 Aime-DEFB 1 Aime-DEFB 103 Aime-DEFB 103 Aime-DEFB 103 Aime-DEFB 107 Aime-DEFB 107 Aime-DEFB 109 Aime-DEFB 109 Aime-DEFB 110	L≪ PGIR-DVIILTQHGTRLFFDFF ELDFKV.D LKSE, V, QEY NY F, Q. SDHY, ARRG, N, A. SYS LP G. FFAAGEP, N.SR, A. SYS LP G. FFAAGEP, N.S, N, A. SYS G. FFAAGEP, N.S	GEKKAEIT SNP-WNRC M.IQVGV FKKK-YA FTRVDGV FKKK-YA R.EQIGR .SGG-RK D.,VVGN KMN-FF. N.EVAL QKS-ILK F.VIGG RAELTPF. S.LQGR L.GQP T.DQIGA RR-R-W. S.IRIAF IR.G-TH. K.FMSY AR.T-TU	Nature peptide > I LPTTEAEGKNEPTDGKND > I INW > I NC > I NCN > I NCN > I NCN > I NOWN > I NOWNO <
Aime-DEFB SPAG11 Aime-DEFB SPAG118 Aime-DEFB 1 Aime-DEFB 103 Aime-DEFB 105 Aime-DEFB 106 Aime-DEFB 106 Aime-DEFB 108 Aime-DEFB 108 Aime-DEFB 110 Aime-DEFB 111 Aime-DEFB 113	I ≪ 2018. 1018. 102	GEK AE IT SNP- WIRE M. LQ VGY FKKK-YA FTRVOGT IYGGK-AK R. EQTGR, SGG-RK D. VVGN, GMFF N. ELYAL, QKSLK F, VTGG, RALLTPF S. LQGR, L. GQP T. DQTGA, RAR-R-W, S. I.RTAF, TR, G-TH K, F,SKY, AR, T-TL W, YTLWKY, T, TEP	Mature peptide >> InTEREGUMPETOGND. INQUESTIONS NE. REX.5. ILQPCORSKODSEDSGFPERH. KKNWK KORFLIEFTIVES SMAILIDIFT. VISSOGPELINKLK. MENDIE NERVENP. INSTRHIL
Aime-DEFB_SPAG11 Aime-DFFB_SPAG118 Aime-DFFB 1 Aime-DFFB 12 Aime-DFFB 12 Aime-DFFB 19 Aime-DFFB 190 Aime-DFFB 190 Aime-DFFB 190 Aime-DFFB 110 Aime-DFFB 111 Aime-DFFB 111 Aime-DFFB 114	EULERV. DUTILITQHGTIRLEFBFC PDIRDVIILITQHGTIRLEFNY PEFNY F.Q.SDHY ARRG	GEKKAE ITSNP-INNE M. LIQVGY FKKK-YA FTRVDGT YGK-KK. R. EQIGK SGG-RK D. VVGN KMM-FF F. VIGG NAELTPF S. LQGR NAELTPF S. LQGR NAELTPF S. L.GDY S. T.RTAF TR. G-TH N. FYAR, T.TL W. YIYAR, T.TL W. YIYR, S. K.	Nature peptide LPTTEAEGKNEPTDGKND. INW. NK. NK. NK. NK. NK. NAKS. NUMARKANDANEDSGFPERIK. NONKY
Aime-DEFB _SPAG11 Aime-DEFB _SPAG118 Aime-DEFB 10 Aime-DEFB 10 Aime-DEFB 10 Aime-DEFB 10 Aime-DEFB 10 Aime-DEFB 10 Aime-DEFB 10 Aime-DEFB 10 Aime-DEFB 110 Aime-DEFB 111 Aime-DEFB 111 Aime-DEFB 113 Aime-DEFB 113 A	Image: Control of the second	GEKK AE LITSNP- INNE MI LQ VVY FKKK-YA FTRV DGT VGK-AK FTRV DGT VGK-AK D, V VGN, VGK KK G, V VGN, VGK LK F, V VGR AEL TPF F, V	Nature peptide > I LPTTEAEGKIM/ETDGGND. > I MR > I BRX > I RCLIS. > I SUMMERCONSEDSGFPERIM. > I KNOWK > I MRCLEFTTREE > I MRCLEFTTREE > I MRCLEFTTREE > I MRCONTEL > I VIENTOVORPULATIONS > I
Aime-DEFB_SPAG11 Aime-DEFB_SPAG118 Aime-DEFB_1 Aime-DEFB_108 Aime-DEFB_108 Aime-DEFB_108 Aime-DEFB_108 Aime-DEFB_110 Aime-DEFB_111 Aime-DEFB_111 Aime-DEFB_111 Aime-DEFB_111 Aime-DEFB_1116 Mime-DEFB_1116 Mime-DEFB_1116 Aime-DEFB_1116 Mime-DEFB_116 Mime-DEFB_106 Mime-DEFB_106 Mime-DEFB_106 Mime-DEF	I ≪ PGIR-DVIILTQHGTIRLFFDFF RUEDFKV. DLKKSEY QEYNY F.Q.SDMY ARRGNYSP	GEKKAE ITSNP-INNE M. I.QVGY FKKK-YA FTRVDGT YGK-AK REQIGK SGG-RK D., VVGN KMH-FF F, VIGK SGG-RK F, VIGK ABELTPF S. LQGK L.GQP S. LGGR ARE.TPF S. LGGR ARE.TPF S. LGGR ARE.TR S. TRTAF TR. G-TH N.Y. CTAF TR. G-TH N.Y. QTAF TR. G-TH N.Y. QTAF S.S. KI N. TQYI, S.S. KI N. TQYI, B.S. SK SK S. TRYI, C.S. SK SK S. TRYI, C.S. SK SK S. TRYI, S.S. KI N. TQYI, S.S. KI S. TENYI, S.S. KI S. TENYI, S.S. KI S. TENYI, S.S. KI S. TENYI, S.S. KI S. TENSK SK S	Nature peptide LPTTEAEGKIKPETDGKND. HQ MR. RKIS. RRISG. ADMILIERTPRE. ADMILIERTPRE. RADILIERTPRE. RADILIERTPRE. RADILIERTPRE. RADILIERTPRE. RADILIERTPRE. RECORTE. LERTER.
Aime-DfF8_50AG11 Aime-DfF9_50AG118 Aime-DfF9_50AG18 Aime-DfF9_103 Aime-DfF9_103 Aime-DfF9_103 Aime-DfF9_103 Aime-DfF9_103 Aime-DfF9_103 Aime-DfF9_113 Aime-DfF9_114 Aime-DfF9_116 Aime-D	EUFKV. D KKSE V Q2Y NYP F.Q. SDMV ARKC N YQY NYP F.Q. SDMV ARKC N YGY NYP F.Q. SDMV ARKC N X MYS VL F.Q. SDMV ARKC N X MYS VL F.Q. SDMV ARKC N X MYS VL F.G. SGMV N X ARK VL F.G. SGMV N X ARK VL F.G. SGMV N X ARK VL SGMV N X X X X X X VL SGMV VL SGMV VL SGMV VL SGMV	GEKK AE LITSNP-INNR M. LQ VVY FKKK-YA FTRV DGT VGK-AK FTRQDGT VGK-AK D, -VVGN, VGKK F, C,	Nature peptide LPTTEAEGKINKPETDGKND. NQL REXK REXKS REXKS REXKS REXKS REXKS REXKS REXKS REXIS NONEPLEPTINE REXINING REXELEPTINE REXELEPTINE REXELEPTINE REXELEPTINE REVENTION
Aime-DEF9_SPAG11 Aime-DEF9_SPAG118 Aime-DEF91 Aime-DEF9103 Aime-DEF9103 Aime-DEF9103 Aime-DEF9103 Aime-DEF9103 Aime-DEF9110 Aime-DEF9110 Aime-DEF9113 Aime-DEF9113 Aime-DEF9116 Aime-DEF916 Aime-DEF9116 Aime-DEF9106 Aime-DEF9106 Aime-DEF9106	I ≪ DVIILTQHGT RLFFDFF PGIN-DVIILTQHGT RLFFDFF F.Q.5DHV ARGC, N.Y.2EYNYY F.Q.5DHV ARGC, R.Y.SSLPF G.FFAACEP RLSRL, N-SSLF G.FFAACEP RLSRL, N-S G.FFAACEP RLS	GEKK AE LICSNP-I-NINR M. LIQ	Msture peptide >> 1 HQN >> 1 HQN >> 1 REXES >> 1
Aime-DEF8_SPAG11 Aime-DEF8_SPAG118 Aime-DEF81 Aime-DEF812 Aime-DEF8120 Aime-DEF8120 Aime-DEF8107 Aime-DEF8107 Aime-DEF8107 Aime-DEF8107 Aime-DEF8110 Aime-DEF8111 Aime-DEF8111 Aime-DEF8114 Aime-DEF8116 Aime-DEF8117 Aime-DEF8117 Aime-DEF8117	L≪ PGIR-DVIELTQHGTWRLFFBFG ELDERV. D KKSEV QEY NYP F.Q. SDMY ARKG N A.VSF VE GFDBC KKIA N A.VS VE GFDBC KKIA N A.VS VE GFDBC KKIA N A.S VE -ARGRKEV ERN A QE US- -ARGRKEV ISO N FAGE VS- 	GEKK AE IT SNP- HMRT MILIQ VGP_FRKK-YA FTRV	Nature peptide LPTTEAEGKIKPETDGKND
Aime-OFF 254611 Aime-OFF 25462118 Aime-OFF 13 Aime-OFF 13 Aime-OFF 132 Aime-OFF 132 Aime-OFF 132 Aime-OFF 136 Aime-OFF 136 Aime-OFF 136 Aime-OFF 131 Aime-OFF 1316 Aime-OFF 1316 Aime-OFF 1316 Aime-OFF 1317 Aime-OFF 1317 Aime-OFF 1317 Aime-OFF 1317	Image: Control of the second	GRXAEIESNP-LWX MIDWXY FXKE-XA REQSXP FXKE-XA REQSXP FXKE-XA REQSXP FXKE-XA NEL	Mature peptide Intra AGGKIMPE TOGNID. Intra AGGKIMPE TOGNID. REX. REX. REX. REX. REX. SME. REX. REX.S. SME.TUPPT (VISSORGED SGFPERIK. KINNIK. KNORE LEPTTREE. SMAIL LIPPT. (VISSORGED INFORMATION OF TOP STATE STA
Aime-DEF8_SPAG11 Aime-DFF8_SPAG118 Aime-DFF8_SPAG118 Aime-DFF8_105 Aime-DFF8_105 Aime-DFF8_105 Aime-DFF8_105 Aime-DFF8_105 Aime-DFF8_105 Aime-DFF8_112 Aime-DFF8_113 Aime-DFF8_114 Aime-DFF8_116 Aime-DFF8_115 Aime-	Image: Control of the second	$ \begin{array}{l} eq:generalized_set_set_set_set_set_set_set_set_set_set$	Nature peptide LPTTEAEGKIKPETDGKND. INW. NK. NK. NK. NK. SKILS. TUPPOKSKOMSEBGGPEBIK. KVRWW. MICHTPT.LINYSOVEPLUKIKLK. .0K. NHCORTE. .0K. .1. STAIT.7UVRVQEPLUKIKLK. .0K. .1. SKTAIT.7UVRVQSKTATTMYSYSKI .1. SKTAIT.7UVRVQSKTATMYSTISKERNOVSENA/SHRASKNLE. .1. SKTIAT.9UVLTRAKENER/INTSTHRASKNLE. .1. SKTIAT.9UVLTRAKENER/INTSTHRASKNLE. .1. SKTAIT.7UVRSVTSTISKERNOVSENA/SHRASKNLE. .1. SKTAIT.7UVRAKENER/INTSTHRASKNLE. .1. SKTAIT.7UVRAKENER/INTSTHERER/INTSTHRASKNLE.
Aime-DEFS _59A611 Aime-DEFS _59A6118 Aime-DEFS 13 Aime-DEFS 13 Aime-DEFS 13 Aime-DEFS 130 Aime-DEFS 130 Aime-DEFS 130 Aime-DEFS 130 Aime-DEFS 130 Aime-DEFS 110 Aime-DEFS 1116 Aime-DEFS 116 Aime-DEFS 116 Aime-DEFS 113 Aime-DEFS 113 Aime-DEFS 113 Aime-DEFS 113 Aime-DEFS 113 Aime-DEFS 113 Aime-DEFS 113 Aime-DEFS 113 Aime-DEFS 124 Aime-DEFS 124	Image: Construction Image: Construction PG1A:=DV1ELTQ:=-HBTIRLEF:=-DFEC VQEY:=-NVP F.Q.:SDNY ARGE:=NVP F.Q.:SDNY ARGE:=	G Y X A & T S W MAR W (2) V WY (X, X, X, X) W (2) V WY (X, X, X) W (2) V WY (X, X, X) W (2) V WY (X, X) W (2	Nature peptide LPTTEAEGKIKETOGKID. NR. REX. REX.S. REX.S. SMULTEPTEVEN REX.S. REX.S. SMULTEPTEVEN REX.S. SMULTEPTEVEN REX.S. SMULTEPTEVENSOPELEPTIKE. REX.S. SMULTEPTEVENSOPELARKLK. .WORKELEPTIKEN. VERVENSOPS.INSTRUKTSVSSIT SEXTEXPS.S. VERVENSOPS.NUK.YDP.SULSYNTSSYSIT J. SKINDOWN.YD.SULSKINSSENVASENKESHKALSKILE. V.SRELIVENTVESKEPÄVINNEKKINSENVASENKALSHKALSKILE. VS.SRELIVENTVESKEPÄVINNEKKINSENVASENKALSHKALSKILE. VS.SRELIVENTVESKEPÄVINNEKKINSENVASENKALSHKALSKILE. VERVENTVESKEPÄVINNEKKINSENVASENKALSHKALSKILE. VERVENTVESKEPÄVINNEKKINSENVASENKALSHKALSKILE. VERVENTVESKEPÄVINNEKKINSENVASENKALSHKALSKILE. VERVENTVESKEPÄVINNEKKINSENVASENKALSHKALSKILE. VERVENTVENTVESKEPÄVINNEKKINSENVASENKALSHKALSKILE.
Aime-DEF9_SPAG11 Aime-DEF9_SPAG118 Aime-DEF91 Aime-DEF9103 Aime-DEF9103 Aime-DEF9103 Aime-DEF9103 Aime-DEF9103 Aime-DEF9103 Aime-DEF9110 Aime-DEF9110 Aime-DEF9110 Aime-DEF9110 Aime-DEF9110 Aime-DEF9110 Aime-DEF9110 Aime-DEF9110 Aime-DEF9121 Aime-DEF9121 Aime-DEF9121 Aime-DEF9123 Aime-DEF9123 Aime-DEF9123 Aime-DEF9123	I PDIR-DVIILTQHGTIRLEFBFC PDIR-DVIILTQHGTIRLEFBAC PDIR-DVIILTQ	$ \begin{array}{l} GFY & \cdots & AFI E \ DN & MRR \\ H & TO & \cdots & DY & FKK & MN \\ H & TO & \cdots & DY & FKK & MN \\ H & TO & \cdots & DY & FKK & MN \\ H & TO & TO & FKK & MN \\ H & TO & TO & TO & STA \\ H & TO & TO & TO & STA \\ H & TO & TO & TO & TO \\ H & TO & TO & TO & TO \\ H & TO & TO & TO & TO \\ H & TO & TO & TO & TO \\ H & TO & TO & TO & TO \\ H & TO & TO & TO & TO \\ H & TO & TO & TO & TO \\ H & TO & TO & TO & TO \\ H & TO & TO & TO & TO \\ H & TO & TO & TO \\ TO & TO & TO & TO \\ TO & TO &$	Mature peptide Influence Influence Influence Rex Rex Rex Rex Influence Rex
Alme-DfF8_50AG11 Alme-DfF9_50AG118 Alme-DfF9150 Alme-DfF9150 Alme-DfF9150 Alme-DfF9150 Alme-DfF9150 Alme-DfF9150 Alme-DfF9150 Alme-DfF9150 Alme-DfF9150 Alme-DfF9116 Alme-DfF9116 Alme-DfF9116 Alme-DfF9116 Alme-DfF9116 Alme-DfF9117 Alme-DfF9117 Alme-DfF91212 Alme-DfF91221 Alme-DfF91221 Alme-DfF91221 Alme-DfF91221 Alme-DfF91224 Alme-DfF91224 Alme-DfF91224 Alme-DfF91224	Image: Control of the second	GPT X AEI C SUP-JMR N NL 12 CG Y AKK AA NL 12 CG Y AKK	Nature peptide LPTTEAGKMKPETOGND
Aime-OFF 25AG11 Aime-OFF 25AG118 Aime-OFF 313 Aime-OFF 313 Aime-OFF 313 Aime-OFF 313 Aime-OFF 310 Aime-OFF 3107 Aime-OFF 3107 Aime-OFF 3113 Aime-OFF 3113 Aime-OFF 3113 Aime-OFF 3116 Aime-OFF 3116 Aime-OFF 3117 Aime-OFF 3117 Aime-OFF 3117 Aime-OFF 3117 Aime-OFF 3117 Aime-OFF 3117 Aime-OFF 3117 Aime-OFF 3127 Aime-OFF 3123 Aime-OFF 3123 Aime-OFF 325 Aime-OFF 325 Aime-OF	I ≪ 2018 UT 0	$ \begin{array}{l} GF(X, \dots, A \in I \in \mathbb{N}^{N} \mbox{ , } Min \\ F(I_{1}, \dots, V_{1}, V, M) \mbox{ , } F(I_{2}, \dots, V_{2}, V) \mbox{ , } F(I_{2}, \dots, V_{2}, V) \mbox{ , } Min \\ F(I_{2}, \dots, V) \mbox{ , } Min \\ F(I_$	Nature peptide Intracedounce Togono. Intracedounce Togono. Rext. Rext. Rext. Schenter. Intracedounce Togono. Intracedounce Togono. Rext. Rext. MOREPLIEPTTREE. Schentle. Intracedounce Togono.
Aime-DEFB_50AG11 Aime-DEFB_50AG118 Aime-DEFB_10 Aime-DEFB10 Aime-DEFB10 Aime-DEFB10 Aime-DEFB10 Aime-DEFB107 Aime-DEFB107 Aime-DEFB107 Aime-DEFB107 Aime-DEFB110 Aime-DEFB110 Aime-DEFB110 Aime-DEFB110 Aime-DEFB110 Aime-DEFB110 Aime-DEFB110 Aime-DEFB121 Aime-DEFB121 Aime-DEFB124 Aime-DEFB124 Aime-DEFB124 Aime-DEFB126 Aime-DEFB126 Aime-DEFB126 Aime-DEFB126 Aime-DEFB127	I PG18-DV10LTQ+HGT\RLFFBFG PG18-DV10LTQHGT\RLFFNY PQ2YNY F.Q.SDMY ARKGNASS	Ger X	Nature peptide LPTTEAEGKIKPETOGKID INA REXIS REXIS SIGNIE PERMEKTIKKE ROMERTIKE REXIS SMULTEPTE / VESVERE REXIS SMULTEPTE / VESVERE REXED INFORTE REXTER INFORTE REXTER VIERVQFVP INSTRILLE RETHELE VIERVQFVP INSTRILLASINGWARKONGTRANGANANANANANANANANANANANANANANANANANAN
Aime-OFF 25AG11 Aime-OFF 25AG118 Aime-OFF 13 Aime-OFF 133 Aime-OFF 133 Aime-OFF 132 Aime-OFF 130 Aime-OFF 130 Aime-OFF 130 Aime-OFF 130 Aime-OFF 131 Aime-OFF 131 Aime-OFF 131 Aime-OFF 131 Aime-OFF 131 Aime-OFF 131 Aime-OFF 132 Aime-OFF 134 Aime-OFF 134	Image: Construction Construction PDIA-DUTIL TQHETIRLEFDECC CQNMP PDIA-DUTIL TQHETIRLEFDECC CQNMP PDIA-DUTIL TQHETIRLEFNMP CQ	$ \begin{array}{l} GFV & \cdots AET [D W - MAR \\ W & [D & \cdots W + W K - X \\ W & [V W - C M] & V (K - X) \\ W & [V W - C M] & V (K - Y) \\ W & [V W - C M] & V (K - Y) \\ W & [V W - V K] & V (K - Y) \\ W & [V W - K] \\ $	Nature peptide LITTEAGGKINGETOGKID. NIL NIL REKK. REKK. <tr< td=""></tr<>
Aime-DEFB_SPAG11 Aime-DEFB_SPAG118 Aime-DEFB_SPAG118 Aime-DEFB_10 Aime-DEFB_10 Aime-DEFB_10 Aime-DEFB_10 Aime-DEFB_10 Aime-DEFB_10 Aime-DEFB_10 Aime-DEFB_10 Aime-DEFB_113 Aime-DEFB_114 Aime-DEFB_114 Aime-DEFB_115 Aime-DEFB_115 Aime-DEFB_115 Aime-DEFB_115 Aime-DEFB_115 Aime-DEFB_115 Aime-DEFB_115 Aime-DEFB_115 Aime-DEFB_125	I PG18DV10LTQHGT/RLFFDF6 PG18DV10LTQHGT/RLFFDF6 PG18DV10LTQNGT/RLFFDF6 ELDFKV. DMKSEV, QEYNYW PG18DV10LTQNGT/RLFFDV10LTQNGT/RLFF	GET.4	Nature peptide LPTTEAEGKIKPETDGKND. /NM. NM. RKKI. RKKI. RKKI. RKKI. SMULTEPTE.VISVOPEDIGFPERHK. VINOWK MICHOTEL I. TUPPCKKROMSEDGGPERHK. VINOWK MICHOTEL I. KININGVERVENKUKLE. .0K. .0K. MICHOTEL .0K.
Aime-DEFS _59A611 Aime-DEFS _59A6118 Aime-DEFS _59A6118 Aime-DEFS 103 Aime-DEFS 103 Aime-DEFS 105 Aime-DEFS 105 Aime-DEFS 105 Aime-DEFS 105 Aime-DEFS 105 Aime-DEFS 105 Aime-DEFS 116 Aime-DEFS 116 Aime-DEFS 116 Aime-DEFS 112 Aime-DEFS 112 Aime-DEFS 123 Aime-DEFS 124 Aime-DEFS 124 Aime-DEFS 124 Aime-DEFS 124 Aime-DEFS 125 Aime-DEFS 126 Aime-DEFS 126 Aime-DEFS 126 Aime-DEFS 128 Aime-DEFS 128 Ai	Image: Construction Ref Image: Construction PG1A:=DV1ELTQ:=-HBTIRLEF:=-DFEC PG2F:=-NP2 F.Q.SDMY ABRC:=NP2 PG2F:=-NP2 G.EXACCF ID: LATE:	$\label{eq:generalized states} \begin{array}{l} Generalized and the set of th$	Nature peptide LPTTEAGKIME TOGNID. NR. NR. REXIS. REXIS. SIGNID. NOME MICOLIE MICOLIE SIGNID.
Aime-DEF9 _SPAC11 Aime-DEF9 _SPAC118 Aime-DEF9 _SPAC18 Aime-DEF9 103 Aime-DEF9 103 Aime-DEF9 105 Aime-DEF9 105 Aime-DEF9 105 Aime-DEF9 113 Aime-DEF9 113 Aime-DEF9 114 Aime-DEF9 116 Aime-DEF9 116 Aime-DEF9 116 Aime-DEF9 116 Aime-DEF9 116 Aime-DEF9 116 Aime-DEF9 117 Aime-DEF9 116 Aime-DEF9 116 Aime-DEF9 116 Aime-DEF9 126 Aime-DEF9 126 Aim	I ≪ 2018. 1018. 102 HEIR L F - BFC PEIR UTIL 102 HEIR L F - BFC PEIR UTIL 102 HEIR L F - BFC E 0. ShYV. 302. 402 102. 102 10	GRY	Mature peptide Interceptide Interception Interception No. Rexts Rexts Interception Interception Interception Interception Interception Rexts Interception
Alme-DfF8_50AG11 Alme-DfF9_50AG118 Alme-DfF9150 Alme-DfF9150 Alme-DfF9150 Alme-DfF9150 Alme-DfF9150 Alme-DfF9150 Alme-DfF9150 Alme-DfF9150 Alme-DfF9150 Alme-DfF9116 Alme-DfF9116 Alme-DfF9116 Alme-DfF9116 Alme-DfF9116 Alme-DfF9122 Alme-DfF9122 Alme-DfF9122 Alme-DfF9122 Alme-DfF9122 Alme-DfF9122 Alme-DfF9122 Alme-DfF9125 Alme-DfF9125 Alme-DfF9125 Alme-DfF9125 Alme-DfF9126 Alme-DfF9126 Alme-DfF9126 Alme-DfF9126 Alme-DfF9126 Alme-DfF9126 Alme-DfF9126 Alme-DfF9126 Alme-DfF9126 Alme-DfF9126 Alme-DfF9126 Alme-DfF9126 Alme-DfF9126 Alme-DfF9126 Alme-DfF9126 Alme-DfF9127 Alme-DfF9128	Image: Second	Ger X	Nature peptide LPTTEAGKIMEPTOGNID
Aime-OFF 25AG11 Aime-OFF 25AG118 Aime-OFF 13 Aime-OFF	Image: Construction Construction PG1ADVITL TQHETRRLFFMIP PG1ADVITL TQHETRRLFFMIP FLIDTRUC MASS	G Y A E I E W. MIN H [1] VIII Y VIII Y Y Y Y H [1] VIII Y VIII Y Y Y Y H [1] Y Y Y Y Y Y Y Y H [1] Y Y Y Y Y Y Y Y Y Y H [1] Y Y Y Y Y Y Y Y Y Y Y Y H [1] Y	Nature peptide Intra AGGKINGE TOGNID. ING Nature peptide Nature perturbation Nature perturbation Nature perturbation Nature petide Nature peptide Nature peptide
Aime-DEFBSPAC111 Aime-DEFBSPAC113 Aime-DEFB_SPAC1 Aime-DEFB_12 Aime-DEFB_12 Aime-DEFB_12 Aime-DEFB_12 Aime-DEFB_107 Aime-DEFB_107 Aime-DEFB_107 Aime-DEFB_107 Aime-DEFB_112 Aime-DEFB_113 Aime-DEFB_113 Aime-DEFB_114 Aime-DEFB_114 Aime-DEFB_114 Aime-DEFB_114 Aime-DEFB_124 Aime-DEFB_124 Aime-DEFB_124 Aime-DEFB_124 Aime-DEFB_124 Aime-DEFB_124 Aime-DEFB_124 Aime-DEFB_125 Aime-DEFB_125 Aime-DEFB_125 Aime-DEFB_126 Aime-DEF	I PG18DV10LTQHGT18LFFDF6 PG18DV10LTQHGT18LFFDF6 PG18DV10LTQDV19.	Ger X AE II SNP-MAR MI 10	Nature peptide LPTTEAGGKINEPTOGKID INM. REXIS REXIS SEXIS TUPPCKSKODKSEDSGFPERHK. KNNWK MICHDELFETTIKE RSMILTPET_VINSVQEPLIKKLK.
Aime-DEFB 50%11 Aime-DEFB 50%018 Aime-DEFB 133 Aime-DEFB 133 Aime-DEFB 130 Aime-DEFB 130 Aime-DEFB 130 Aime-DEFB 130 Aime-DEFB 130 Aime-DEFB 131 Aime-DEFB 131 Aime-DEFB 131 Aime-DEFB 131 Aime-DEFB 131 Aime-DEFB 131 Aime-DEFB 132 Aime-DEFB 133 Aime-DEFB 134 Aime-DEFB 1	Image: Construction Construction PDIA-DUTIL TQHETIRLEFDECC CQ-YNMP F.Q. TOWN OTGNAVY CQ-YNMP F.Q. TOWN OTGNAVY CQ-YNMP G.E.RACCPI RLSRX, RAVRE CQ-Y	G Y A E I C MNR TH A Y	Nature peptide LIFTEAGKIMPETOGNID. NIL
Aime-DEF9 _SPAC11 Aime-DEF9 _SPAC118 Aime-DEF9 _SPAC118 Aime-DEF9 103 Aime-DEF9 103 Aime-DEF9 105 Aime-DEF9 105 Aime-DEF9 105 Aime-DEF9 110 Aime-DEF9 113 Aime-DEF9 114 Aime-DEF9 116 Aime-DEF9 121 Aime-DEF9 122 Aime-DEF9 122 Aime-DEF9 122 Aime-DEF9 122 Aime-DEF9 123 Aime-DEF9 125 Aime-DEF9 125 Aime-DEF9 126 Aime-DEF9 126 Aime-DEF9 126 Aime-DEF9 126 Aime-DEF9 127 Aime-DEF9 126 Aime-DEF9 126 Aime-DEF9 126 Aime-DEF9 126 Aime-DEF9 127 Aime-DEF9 126 Aime-DEF9 126 Aime-DEF9 126 Aime-DEF9 126 Aime-DEF9 126 Aime-DEF9 126 Aime-DEF9 126 Aime-DEF9 130 Aime-DEF9 134 Aime-DEF9 136 Aime-DEF9 136 Aime-DEF9 136 Aime-DEF9 136 Aime-DEF9 136 Aime-DEF9 136 Aime-DEF9 136	I PEIA OTIL 1/0 HEIR LF FFE PEIA OTIL 1/0 HEIR FFE FFE DEIA OTIL 1/0 HEIR FFE	$ \begin{array}{c} Gr (Y, \dots, A \in I \subseteq N) & \text{Mark III} \\ W & 10 & \dots & V & W & (X, N) \\ W & 10 & \dots & V & W & (X, N) \\ W & 10 & \dots & V & V & (X, N) \\ W & 10 & \dots & V & (X, N) & (X, $	Nature peptide International International International Reconstructional Reconstreconstructional Reconstrecon
Aime-DEFS _SPAC11 Aime-DEFS _SPAC118 Aime-DEFS _SPAC18 Aime-DEFS 103 Aime-DEFS 103 Aime-DEFS 105 Aime-DEFS 105 Aim	Image: Construction Ref Image: Construction PG1A:=DV1ELTQ:=-HGTRRLFF:=-DF6C PG2F:=-NP F.Q.SDMY ABRC:=	G Y L	Nature peptide LPTTEAGKMKPETOGND. Non. Non. REXES. REXES. NUMEDIFIERD REXES. NONELLEPTIVES. REXED. NONELLEPTIVES. REXES. NONELLEPTIVES. REXES. SWICDETE. VERNOWSCONSEDSGEPERINK. NONELLEPTIVES. REXELS. SWICDETE. VERNOWS. VERNOWS. NEXTREMENT. VERNOWS. VERNOWS. NEXTREMENT. VERNOWS. VERNOWS. VERNOWS. VERNOWS. VERNOWS. SECTOR VERNOWS. VERNOWS. <td< td=""></td<>
Aime-DBFR 50AG11 Aime-DBFR 50AG118 Aime-DBFR 50AG118 Aime-DBFR 51 Aime-DBFR 103 Aime-DBFR 104 Aime-DBFR 104 Aime-DBFR 104 Aime-DBFR 104 Aime-DBFR 113 Aime-DBFR 114 Aime-DBFR 114 Aime-DBFR 114 Aime-DBFR 114 Aime-DBFR 114 Aime-DBFR 114 Aime-DBFR 115 Aime-DBFR 115 Aime-DBFR 115 Aime-DBFR 115 Aime-DBFR 115 Aime-DBFR 115 Aime-DBFR 125 Aime-DBFR 125 Aime-DBFR 128 Aime-DBFR 128 Aime-D	Image: Construction PG12	Gr V AE I. S. W. MNR N. TOT DOT VIEL V. M. MNR N. TOT DOT VIEL V. GGL AM N. TOT DOT VIEL V. GGL AM N. D TOG A. M.	Nature peptide INTERAGGNINE TOGNID. IND IND REX. REX. REX. REX. SMILLIPET. INSTRUCTION OF DEGREE NEXT NOT STATUS TO STATUS T
Alme-DFF 130 Alme-DFF 131 Alme-DFF 131 Alme-DFF 131 Alme-DFF 131 Alme-DFF 131 Alme-DFF 131 Alme-DFF 132 Alme-DFF 132 Alme-DFF 132 Alme-DFF 132 Alme-DFF 132 Alme-DFF 132 Alme-DFF 132 Alme-DFF 132 Alme-DFF 132 Alme-DFF 133 Alme-DFF 138 Alme-DFF 138 Alme-	Image: Construction ELDERV. OL INCS. Y. QEY NYS PG18-DV10LTQHGTWR.LFF Y. QEY NYS Y. SPS NYS F. Q. SDMY ARRG N. NYS Y. NYS Y. SPS Y. SPS F. Q. SDMY ARRG N. NYS Y. SPS Y. SPS Y. SPS GTHRENQ GROW N. A. Y. SOLTARE Y. SNLTRE Y. SNLTRE Y. SNLTRE J. SLADERE RKRN Y. SLADERE Y. SNLTRE Y. SNLTRE Y. SNLTRE SLADERE Y. SNLTRE Y. SNLTRE Y. SNLTRE Y. SNLTRE Y. SNLTRE SLADERE Y. SNLTRE Y. SNLTRE Y. SNLTRE Y. SNLTRE Y. SNLTRE SLADERE Y. SNLTRE Y. SNLTRE Y. SNLTRE Y. SNLTRE Y. SNLTRE SLADERE Y. SNLTRE Y. SNLTRE Y. SNLTRE Y. SNLTRE Y. SNLTRE SLADERE Y. SNLTRE Y. SNLTRE Y. SNLTRE Y. SNLTRE Y. SNLTRE SCHOPERE Y. SNLTRE Y. SNLTRE Y. SNLTRE Y. SNLTRE	GRY A EL SUD-JANN NL 12 GLY YAK A A NL 12 GLY YAK A NL 12	Nature peptide LPTTEAGKMKPETOGND

Figure 1. Amino acid sequence alignment of β -defensin proteins in giant panda. The name of the β -defensins starts with the abbreviation of the species' Latin name followed by the name of the β -defensin. Dots and dashes represent identity and alignment gaps compared to Aime-DEFB_SPAG11, respectively. Regions corresponding to the signal peptide, pro-piece, and mature peptide domains are indicated. Light grey: conserved residues (frequency \geq 70%); dark grey: six highly conserved cysteine motifs.

assess their immunological adaptation and fitness, which ultimately provides guidance for captive breeding and reintroduction programs^{14–16}.

Despite the promising applications of β -defensins in animal health, research on these immune genes in the giant panda has been largely overlooked. The number of β -defensin gene loci in various databases is currently large but many have an incomplete gene structure, and it is therefore difficult to target suitable genes for further study. With the advent of genome sequencing, the development of bioinformatics tools, and our giant panda BAC library¹⁷, we were able to depict the full repertoire of this subfamily. Furthermore, we aimed to identify any giant panda β -defensin genes that have adaptively evolved to cope with changing pathogens, as a dietary switch from meat to bamboo may have generated a microflora distinct to the giant panda¹⁸.

Results

Characterization of the giant panda β -**defensin genes.** Thirty-six β -defensins with intact structures were identified in the giant panda genome (Fig. 1 and Supplementary Table S1). As in other mammals, most β -defensin genes in giant panda have two exons that encode a signal peptide, a short pro-piece, and a mature peptide domain¹. One exception is the sperm-associated antigen 11B (SPAG11B); in different mammals, this peptide has three exons with a long pro-piece encoded by the second exon. It is unique that DEFB1 in the giant panda (Aime-DEFB1) has a long signal peptide. Although the signal peptide domain in Aime-DEFB1 could not be detected using SignalP, the 36th to 56th residues of the peptide resembled the structure of a signal peptide (Fig. 1). An alignment of the sequence with DEFB1 in the polar bear showed that the elongated Aime-DEFB1 signal peptide might result from a Met-to-Arg mutation at the 33rd residue. The expression of the *DEFB1* gene was also detected in our study, providing evidence of a functional *DEFB1* gene in the giant panda (Table 1).

These 36 β -defensin genes are distributed on seven scaffolds: scaffold 1375, 335, 3432, 3401, 1318, 2426 and 2713 (accession numbers GL192431.1, GL193056.1, GL194707.1, GL195409.1, GL192588.1, GL194420.1, and GL195214.1, respectively). As the BAC clone (1054F4) covered scaffold 3401 and also bridged scaffolds 3432 and 1318, a total of five giant panda β -defensin gene clusters were observed (Fig. 2). According to our orthological analysis, these five gene clusters should be distributed on four different chromosomes (Fig. 2). The β -defensin

Tissue	Aime- DEFB1	Aime- DEFB103	Aime- DEFB139	Aime- DEFB140
Blood		+		
Liver		+		
Ovary	+	+		
Spleen	+		+	
Kidney	+	+	+	
Stomach	+		+	
Pancreas	+			+

Table 1. Expression patterns of four β -defensin genes in the giant panda. A plus symbol (+) indicates the expression of the β -defensin in the indicated tissue.



Figure 2. Syntenic relationships between β -defensins in the giant panda (*A. melanoleuca*), dog (*Canis lupus familiaris*), cattle (*Bos Taurus*), mouse (*Mus musculus*), and humans (*Homo sapiens*). Vertical bars represent defensin genes and their orientation is indicated by a black triangle. The location of each gene, cluster, and the BAC clone 1054F4 (grey shade) is annotated and their length is drawn to scale (upper right corner). When a gap between two neighbouring genes was larger than 100 kb, it is noted as "//". Paralogs are depicted with the same colour, and orthologs are noted with the same name based on the results of phylogenetic analyses (Supplementary Fig. S1). The number in the bracket indicates the original number assigned by NCBI.

genes in the giant panda had the strongest synteny with those in the dog, as almost all of the β -defensin genes in these two species showed one-to-one orthological conservation (Fig. 2), in contrast to the many gene duplications that occurred in humans, mice and cattle (Fig. 2).

When the reconstructed phylogeny of β -defensins in humans, mice, cattle, dogs, and giant pandas was evaluated, only *DEFB110*, *DEFB113*, *DEFB116*, *DEFB119*, *DEFB123*, *DEFB124*, *DEFB125*, *DEFB129*, and *DEFB131* dispayed a one-to-one orthology (Fig. 3). These genes mostly belonged to one β -defensin gene cluster that was evolutionarily the youngest of the clusters identified¹². Other genes either had duplications or were lost in some species. For example, *DEFB104*, *DEFB115*, *DEFB118*, and *DEFB122* were not represented in the giant panda genome, whereas in mice, cattle, and humans there were many gene duplications of *DEFB4* were present in cattle, whereas the mouse *Defb4* was duplicated and then diverged during evolution (Fig. 3). There were also several mouse-specific gene duplications, including *Defb37-40* and *Defb9-10* (Fig. 3). In humans, *DEFB4*, *DEFB130* and *DEFB103-107* exist as two copies in the genome. Figure 3 also shows that some neighbouring defensins such as *DEFB4* and *DEFB103*, *DEFB116* and *DEFB116*-like, and *DEFB126* and *DEFB126*-like clustered with high bootstrap support values, indicating that *cis* duplication was common during the evolution of immune gene families¹⁹.



Figure 3. Neighbour-joining tree of β -defensins in the giant panda, dog, cattle, mouse, and humans. The chicken (*Gallus gallus*) β -defensin 1 (i.e. Gaga-DEFB1) is used as an outgroup and bootstrap values under 40 are not shown. Genes conserved as one-to-one orthologs or which only have two copies in some species are collapsed into one branch, whereas branches with duplicated genes in cattle or mice remain expanded. On expanded branches, the name of the genes starts with the abbreviation of the species' Latin name followed by the β -defensin name. For detailed evolutionary relationships for each gene, please refer to Supplementary Fig. S1. Lineages from the same chromosome are depicted in the same colour.

Expression pattern of β -**defensins in the giant panda.** We only detected the expression of four β -defensin genes in the various tissues investigated in the giant panda used in this study. In the giant panda, *DEFB1*, *DEFB103*, and *DEFB139* were expressed in more tissues than *DEFB140* (Table 1). Because the health status of the studied individual and sample size could affect the results of β -defensin gene expression profiling, we BLAST-searched these gene sequences against several giant panda tissue transcriptome datasets. Although no transcriptome data were found for the spleen, kidney and pancreas, we still observed a broad spectrum of expression of the *DEFB1* and *DEFB103* genes; *DEFB1* was expressed in the liver (accession number SRX1208869), ovary (SRX1208780), and pituitary (SRX1208761), while *DEFB103* was expressed in the blood (SRX542925), skin (SRX1208682), and tongue (SRX1208772). The expression of *DEFB1* and *DEFB139* in the digestive tract. However, the expression of *DEFB1* and *DEFB139* in the digestive system observed in our study could have been due to acute haemorrhagic enteritis present in the specific giant panda used in the study.

Evolutionary analyses of the expressed giant panda defensin genes. This represents the first study to identify giant panda β -defensins important for defending against gastrointestinal disease, which is common in giant pandas. We next further analysed these four genes using phylogeny and identified their different evolutionary history. The Z-test showed that for each gene, the mean dS was larger than the mean dN, suggesting a significant purifying selection. However, at the whole-sequence level, several sites were under episodic positive selection, and the BUSTED analysis indicated episodic positive selection for *DEFB1*, *DEFB103*, and *DEFB139* (Table 2). Episodic positive selection on *DEFB1* was most frequent in several taxa, whereas for *DEFB139*, periodic positive selection appeared to be confined to genes in carnivores (Fig. 4).

	Z-test of selectio	BUSTED	
Gene	Test ¹ /Test ²	p^1/p^2	p ¹ /p ²
DEFB1	3.42/3.28	0.000/0.001	0.004/0.011
DEFB103	6.02/6.46	0.000/0.000	0.006/0.020
DEFB139	3.55/2.64	0.000/0.005	0.021/0.064
DEFB140	4.35/4.04	0.000/0.000	0.600/0.756

Table 2. Results of the Z-test for selection and BUSTED analyses. The "Test" column shows the result of dS-dN, and p < 0.05 indicates significant negative selection. P-values in the BUSTED column smaller than 0.05 suggest episodic positive selection on the gene. Superscripts 1 and 2 indicate the analyses that were used for the entire sequence or mature peptide domain, respectively.

When only the mature peptide domain was analysed, a significant episodic positive selection was no longer detectable for DEFB139 (Table 2), and relatively fewer branches (i.e. three out of seven) of DEFB139 remained under episodic positive selection (Fig. 4). This suggests that nonsynonymous substitutions in the signal peptide played an important part in the evolution of the DEFB139 gene; thus, we analysed the selective pressure on the signal peptide region of DEFB139 (Supplementary Methods). Our results showed that the DEFB139 signal peptides in non-carnivores were under significant purifying selection (dS-dN = 2.54, p = 0.01), whereas the purifying selection for this signal peptide in Carnivora was reduced (dS-dN = 1.55, p = 0.06). Moreover, the signal peptide region in Aime-DEFB139 (the giant panda DEFB139) diverged the most from that of non-carnivores (Supplementary Table S2). Therefore, the complete Aime-DEFB139 coding sequence was evaluated first using branch models to reflect the selective pressure on this gene. We found that among the several two-ratio models tested, only the two-ratio model that tested the ω (dN/dS) value in the giant panda lineage out-competed the null one-ratio model (Fig. 5a,b). The significantly higher dN/dS rate in the giant panda lineage suggested a different evolutionary history from that in other mammalian lineages; however, this rate was not significant when either the mature peptide (dN/dS = 999, p = 0.09) or signal peptide domain (dN/dS = 999, p = 0.13) of Aime-*DEFB139* gene was analysed separately. This indicates that the unique evolutionary history of DEFB139 in the giant panda contributed to the nonsynonymous substitutions throughout the whole sequence rather than in a single domain.

Because the branch model only compares averaged ω values for whole gene sequences, we applied RELAX, the Branch-Site Model, and MEME, which account for the selective pressure on specific sites, to examine changes in selective pressure and to recognize sites where selection has occurred. Contrary to the branch model analyses, RELAX only suggested a near-significant positive selection on the entire Aime-*DEFB139* coding sequence, but this selective pressure was the most strengthened (Supplementary Table S3). Furthermore, when the whole coding sequence was examined, the Branch-Site Model (Bayes Empirical Bayes, BEB = 0.93) and MEME (p = 0.14) indicated that the 29th residue of the Aime-DEFB139 mature peptide was most likely subjected to diversifying selection (the two methods have critical significance levels of BEB > 0.95 and p < 0.10, respectively).

Physiochemical properties and structure of the giant panda DEFB139 mature peptide. The 29th residue is an Arg and only presents in the giant panda DEFB139 and large brown bat DEFB139; in all other mammals tested, a Pro is retained at this position. This Pro-to-Arg mutation is likely to represent a monomorphism (Supplementary Note), and by acquiring this additional positively charged residue, the Aime-DEFB139 mature peptide displays reduced instability and a higher isoelectric point (Supplementary Table S4). According to the instability index, Aime-DEFB139 is still unstable; however, proteins such as RNase A and β -defensins are stabilized in their native forms by several disulfide bridges²⁰. Such structures are known to make proteins resistant to degradation, which results in a misleading instability index^{20,21}. Therefore, the Aime-DEFB139 mature peptide may or may not be unstable following the Arg mutation. Moreover, similar to the Aime-DEFB139 mature peptide, an Arg rather than a Pro between Met and Gly residues could make proteins more resistant to degradation²⁰. Similarly, the increased isoelectric point alone cannot guarantee a higher antimicrobial potency, but the isoelectric point and antimicrobial potency of β -defensins are positively related²². In terms of the isoelectric point and instability index, the Aime-DEFB139 mature peptide differs significantly (p=0.00) from its orthologs according to the calculated Mahalanobis distances (D²; Fig. 5c), which indicated an increased antimicrobial activity for this protein in the giant panda. Moreover, our modelling results suggested that the Aime-DEFB139 mature peptide displays a different molecular surface, and its second β -sheet had appeared after the point mutation had occurred (Fig. 5d). The increased surface charge and hydrophobicity, as well as its stabilized second β -sheet, may also be related to the enhanced antimicrobial potency of Aime-DEFB139^{22,23}.

Antibacterial activity of the giant panda DEFB139. To examine the influence of the Pro-to-Arg mutation on the antimicrobial activity of the Aime-DEFB139 mature peptide, we attempted to synthesize high purity Aime-DEFB139 and Arg-to-Pro-substituted Aime-DEFB139 (i.e. the Aime-DEFB139 with its Arg residue replaced by Pro) with the native folding pattern, but failed. This is because β -defensins contain six Cys residues, which can be easily oxidized and lead to isoforms with distinctive disulfide pairings²⁴. Moreover, the additional positively charged Arg in Aime-DEFB139 could have induced an electrostatic repulsion that prevented the required hydrophobic packing during the *in vitro* chemical synthesis; and the Cys potentially could not get close enough to form disulfide bonds²⁴, which resulted in partially oxidized variants that also lowered the product's purity.

Considering that the antimicrobial activity of β -defensins against some bacteria is independent of the presence and pattern of disulfide bridges^{21,22}, we synthesized the two peptides with their Cys residues protected by acetamidomethyl (Acm). Although these peptides will maintain their linear form, as Acm prohibits the formation



Figure 4. Maximum likelihood trees of the DEFB1, DEFB103, DEFB139, and DEFB140 genes. Purple, green, red, vellow, orange, blue, and grey indicate Euarchonta, Rodentia, Lagomorpha, Chiroptera, Perissodactyla, Carnivora, and Cetartiodactyla, respectively. Support values under 40 are hidden. Branches under episodic positive selection (empirical Bayesian factor, EBF > 60), irrespective of whether the mature peptide region or entire sequence were used in the analyses, are shown in blue. Branches in red indicate lineages with EBF > 60 only when the entire sequence was analysed. The Latin species names and their abbreviations are as follows: Acinonyx jubatus (Acju), A. melanoleuca (Aime), Aotus nancymaae (Aona), Balaenoptera acutorostrata (Baac), B. taurus (Bota), Callithrix jacchus (Caja), Camelus ferus (Cafe), C. lupus familiaris (Calufa), Capra aegagrus hircus (Caaehi), Carlito syrichta (Casv), Cavia porcellus (Capo), Cebus capucinus (Ceca), Ceratotherium simum simum (Cesisi), Chlorocebus sabaeus (Chsa), Cricetulus griseus (Crgr), Dasypus novemcinctus (Dano), Echinops telfairi (Ecte), Elephantulus edwardii (Eled), Eptesicus fuscus (Epfu), Equus africanus asinus (Eqafas), Equus ferus caballus (Eqfeca), Erinaceus europaeus (Ereu), F. catus (Feca), Fukomys damarensis (Fuda), Galeopterus variegatus (Gava), Gorilla gorilla (Gogo), Heterocephalus glaber (Hegl), Hipposideros armiger (Hiar), H. sapiens (Hosa), Jaculus jaculus (Jaja), Leptonychotes weddellii (Lewe), Lipotes vexillifer (Live), Macaca mulatta (Mamu), Manis javanica (Maja), Marmota marmota (Mama), Mesocricetus auratus (Meau), Microcebus murinus (Mimu), Microtus ochrogaster (Mioc), M. musculus (Mumu), Mustela putorius furo (Mupu), Myotis brandtii (Mybr), Myotis capaccinii (Myca), Myotis davidii (Myda), Myotis lucifugus (Mylu), Nomascus leucogenys (Nole), Ochotona princeps (Ocpr), Octodon degus (Ocde), Odobenus rosmarus (Odro), Orcinus orca (Oror), Orycteropus afer (Oraf), Oryctolagus cuniculus (Orcu), Otolemur garnettii (Otga), Ovis aries (Ovar), Panthera tigris (Pati), Pantholops hodgsonii (Paho), Papio anubis (Paan), Peromyscus maniculatus (Pema), Physeter macrocephalus (Phma), Pongo pygmaeus (Popy), Propithecus coquereli (Prco), Pteropus alecto (Ptal), Pteropus vampyrus (Ptva), Rattus norvegicus (Rano), Rhinolophus sinicus (Rhsi), Rousettus aegyptiacus (Roae), Saimiri boliviensis (Sabo), Spalax galili (Spga), Sus scrofa (Susc), Tupaia chinensis (Tuch), Tursiops truncatus (Tutr), Ursus maritimus (Urma), Vicugna pacos (Vipa).



Figure 5. Branch model comparisons of the DEFB139 gene and changes in the Aime-DEFB139 mature peptide induced by the point mutation. (a) Branch model comparisons using the entire coding sequence. Model A is a one-ratio model. Models B to K are two-ratio models. The tested branches are shown in the brackets. $\omega 1$ and ω^2 are ω values for tested and reference lineages, respectively. LR and df represent the differences of the two models in likelihood ratio and degree of freedom, respectively. Only the two-ratio model of Aime-DEFB139 had a significantly better fit than the null model in describing the selective pressures on DEFB139 orthologs. (b) Scatter plot of dN/dS values from model C for each species. The red dot is Aime-DEFB139 and the reference line is represented by dots with dN/dS = 1. (c) Physiochemical properties of the DEFB139 mature peptide in different carnivores. Original and manually adjusted (i.e. replacement of the 29th Arg to Pro) Aime-DEFB139 variants are represented by filled red circles and squares, respectively. The remaining carnivore DEFB139 homologs are represented by filled blue circles. D_2^2 and D_1^2 are the Mahalanobis distances calculated with and without the Arg-to-Pro-substituted Aime-DEFB139, respectively, and the critical values calculated for these datasets according to Eq. (1) are 7.46 (df1 = 3, df2 = 10, $\alpha = 0.01$) and 6.76 (df1 = 3, df2 = 9, $\alpha = 0.01$), respectively. Therefore, only the Aime-DEFB139 mature peptide was found to be an outlier with regard to physiochemical properties, including the instability index and isoelectric point. Exact measurements of the physiochemical properties and Mahalanobis distances for each DEFB139 mature peptide are provided in Supplementary Table S4. (d) Tertiary structure model comparisons. Models on the left and right depict the molecular surface and tertiary structure of the mature peptide for the original and Arg-to-Pro-substituted Aime-DEFB139, respectively. Different residues and secondary structures are indicated by different colours.

of disulfide bridges, this modification will not change the peptides' net charge, a main factor (rather than disulfide bonding) that affects the antimicrobial potency of β -defensins^{21,22}. Therefore, we can still evaluate the effect of the increased net charge in Aime-DEFB139 due to the Pro-to-Arg mutation. Furthermore, as the peptides were kept in their linear form, isoforms and partially oxidized variants did not occur, which has led to high purity products. The synthesis of the Acm-protected Aime-DEFB139 produced a 97.8% pure product with a mass of 5608 Da (the theoretical value is 5,607.2 Da, and this difference was within the error range²⁵; Supplementary Fig. S2). The Acm-protected Aime-DEFB139 in which the Arg-to-Pro substitution was engineered was obtained with 97.3% purity and with a mass of 5,548.9 Da (theoretically, the mass is 5,548.1 Da; Supplementary Fig. S2).

The CD spectra of the two synthesized peptides are very similar (Supplementary Fig. S3), and their secondary structure only differs slightly, as calculated using the CDPro packages. Both peptides contain almost the same fractions of α -helix (about 7%) and β -turn (about 25.3%), while Aime-DEFB139 is a little less unordered and exhibits a slightly higher proportion of β -sheet than the Aime-DEFB139 containing the Arg-to-Pro substitution (26.1% and 23.6%, respectively).

The two synthesized peptides suppressed bacterial growth at low concentrations. However, to kill substantial loads of *Staphylococcus aureus*, *Escherichia coli* and *Yersinia enterocolitica* (>50%), they still had to reach a high concentration (above 30 mg/L) which may be non-physiological (Fig. 6a–d). Although in statistical terms the antimicrobial potency of Aime-DEFB139 against *S. aureus* was significantly higher than that of the Arg-to-Pro-substituted Aime-DEFB139 (Fig. 6b), this enhancement in potency was physiologically minor.

Discussion

Our study initially analysed the annotation of the β -defensin gene family in the giant panda genome and the evolutionary relationships between these genes and other mammalian β -defensin genes. The gene family has undergone gain and loss evolutionary process which are typical for gene families involved in immune function²⁶. Although the *DEFB104*, *DEFB115*, *DEFB118*, and *DEFB122* genes in the giant panda have been lost



Figure 6. Antimicrobial activities of the Acm-protected Aime-DEFB139 and Arg-to-Pro-substituted Aime-DEFB139 against (**a**) *E. coli*, (**b**) *S. aureus*, (**c**) *K. pneumoniae* and (**d**) *Y. enterocolitica* at different time points. The diluted strains were cultivated with different β -defensin concentrations (0–128 mg/L) for 24 h. At different time points, the optical density was measured at 600 nm. The turbidity ratio in the wells containing each β -defensin to those without the β -defensin peptides was calculated as the survival percentage. A plus symbol (+) indicates that a particular β -defensin at a certain concentration had a statistically significant antimicrobial activity (detailed p-values are in Supplementary Table S5). An asterisk (*) indicates that at a certain concentration, Aime-DEFB139 had a statistically significantly (P < 0.05) higher antimicrobial potency than the Arg-to-Pro-substituted Aime-DEFB139 (detailed p-values are shown in Supplementary Table S6).

.....

(Supplementary Fig. S1), this is not unique, as further BLAST searches showed that carnivores such as dogs, cats, polar bears, and ferrets have also lost some of these genes over their evolutionary history. Because conserved β -defensins may not provide enough information for a clear and robust resolution between orthologs, a poorly supported orthologous relationship between some defensins in the giant panda and the dog (e.g. *DEFB140*,

DEFB110, and DEFB107) was observed (Supplementary Fig. S1). Nevertheless, the DEFB140, DEFB110, and DEFB107 genes in the giant panda are most similar to their orthologs in the polar based on the results of our BLAST searches. Therefore, the conserved synteny and well-supported orthology suggests that the giant panda genome still retains the typical carnivore β -defensin gene family. This was expected because, similar to many other immune gene families, the purifying selection on the β -defensin gene family resulted in structural and functional conservation²⁶.

Generally, although carnivore β -defensin sequences are conserved, we detected a significant positive selection on the Aime-*DEFB139* gene through branch model comparisons (Fig. 5). However, the significant increase in selective pressure on the Aime-*DEFB139* gene should be attributed not only to the nonsynonymous substitutions in the mature peptide, but also to those in the signal peptide domain. The reduced purifying selection on the signal peptide may be related to changes in secretion efficiency or expression specificity²⁷. We hypothesize that the mutation at the 29th residue in the Aime-DEFB139 mature peptide may be related to an increase of antimicrobial potency.

We speculate that the point mutation identified in the Aime-DEFB139 mature peptide is pathogen-driven and crucial for enhancing the peptide's antimicrobial potency. First, the residue is in the mature peptide where the molecule interacts with the pathogens²⁸. Second, the Pro-to-Arg substitution made the Aime-DEFB139 mature peptide unique by enhancing its isoelectric point and stability (Fig. 5c,d). Several studies have suggested that antimicrobial potency can be positively correlated with the cationic charge and stability of β -defensions; ^{21,23,24,29-31} therefore, Aime-DEFB139 has a distinctive antimicrobial activity when compared to its orthologs in other carnivores. Third, in DEFB139 homologs present in other carnivores, replacing the 29th residue of the mature peptide with an Arg does not alter its secondary structure. However, this is not the case for Aime-DEFB139, where a second β -sheet appears in the peptide after the replacement of Pro by Arg (Fig. 5d). CD spectroscopy also suggested that the Pro-to-Arg mutation has changed the β -sheet content of the Aime-DEFB139. Therefore, this indicates that the Arg residue could be important for the stability of the β -sheet in Aime-DEFB139. If the Aime-DEFB139 mature peptide dimerizes through the second β -sheet similar to the human β -defensin 3, which is the product of the human DEFB103 gene, when attacking microbes²², this very site could be critical for the function of Aime-DEFB139. Lastly, its relatively broad spectrum of expression (Table 1), and especially its expression in the stomach, where diverse and new pathogens are confronted by the host system, may have promoted the high antimicrobial potency of Aime-DEFB139.

Branch-site model-based analyses did not identify any positive selection on Aime-DEFB139. This is probably because the positive selection may have been masked by the strong purifying selection. If nonsynonymous substitutions are exclusive to Aime-DEFB139, the substitution could be regarded as a chance appearance rather than being caused by positive selection, even if the latter is true³². For example, the 29th residue of the DEFB139 mature peptide was only mutated in the giant panda and large brown bat, while remaining conserved in all other mammals; indicating that the positive selection at this site is thus masked by the purifying selection.

Branch-site based analyses also require sufficient proportions of nonsynonymous substitutions caused by significant positive selection for the results of a tested lineage to be statistically significant³³⁻³⁵. The significant change in β -defensing energy in some organisms is due to distinctive transformations in their lifestyle and/or living environment. For example, β -defensins in cattle and mice have duplicated under positive selection as they adapted to their specialized niches, such as rumen development and inhabiting environments with complex microbes, respectively^{4,12,36}. The expanded number of AvBD1 and AvBD3 genes in songbirds such as the zebra finch and hwamei is thought to be linked with structures required to maintain their singing trait, such as a highly developed syrinx³⁷. Furthermore, as the ocean has a microbial environment very different from that of terrestrial habitats, the selective pressure on defensins, such as DEFB103 and DEFB140, in cetaceans has been significantly relaxed (Supplementary Table S7 and Fig. S4), which has ultimately led to the disappearance of these genes (Fig. 4). In comparison, although the giant panda has adopted a bamboo-dominant diet, the change in its intestinal microbiota appears trivial³⁸; thus, there may not have been a substantial change in the living environment to generate a strong selective pressure on the β -defensing ene family. Even if a special gut microbiome has evolved in giant pandas, the change may only have occurred approximately four million years ago (MYA)³⁹, whereas the mammalian β -defensing ene family was established more than 100 MYA^{4,9,40}. This indicates that changes in microbial composition may not provide a sufficiently long selective pressure to overwhelmingly alter the β -defensions in the giant panda. Thus, the positive selection was not strong and long enough for giant panda defensins to accumulate substantial substitutions under dominant purifying selection.

Indeed, there may be no need for the giant panda to accumulate many nonsynonymous substitutions in its β -defensins for these to be different from their homologs in other carnivores. In some immune peptides, including β -defensins, a single amino acid substitution is sufficient to alter their molecular potency against pathogens³⁰. Targeting a broad range of pathogens, Aime-DEFB139 may not need to change significantly under diversifying selection to cope with new pathogens, and an enhanced antimicrobial activity resulting from a point mutation could be sufficient for this coping ability. To show that the Pro-to-Arg mutation in Aime-DEFB139 has changed the peptide's antimicrobial potency, we synthesized the Aime-DEFB139 mature peptide and the Arg-to-Pro-substituted Aime-DEFB139 with their Cys residues protected by Acm, and then compared their antimicrobial activity against *E. coli*, *S. aureus*, *Y. enterocolitica*, and *K. pneumoniae* using the broth microdilution assay. Our results suggested that the increase in net charge caused by the Pro-to-Arg mutation indeed can enhance the peptide's potency against certain bacteria, although the enhancement was minor.

The minor difference in antimicrobial potency between the two synthesized peptides and their low efficacy in killing bacteria may be due to the lack of disulfide bonding, since only after correct folding and dimerization can some β -defensins exhibit enhanced antimicrobial potency^{21,41,42}. Compared with the Pro-containing Aime-DEFB139 peptide, a correctly folded Aime-DEFB139 peptide could have a much higher antimicrobial potency, as it has a higher net charge and more stable β -sheets, which may enable its dimerization. Another

explanation for the minor difference in antimicrobial potency between the two peptides could be that rather than affecting antimicrobial activities, the Pro-to-Arg mutation may mainly influence the functions that require a higher order structure (e.g. chemotactic activities)²⁴, as the mutation affects the stability of the peptide's secondary structure. The best but also the most labour-intensive, time consuming, and costly way to resolve the above questions regarding the functions of the Aime-DEFB139 peptide would be to selectively form disulfide bonds to ensure its native folding pattern²².

In conclusion, *DEFB139* is likely to represent a special β -defensin gene in the giant panda, and its expression and function are worth further study to enhance the health and fertility of giant pandas. As the dietary supplementation of butyrate enhances disease resistance by up-regulating β -defensins in the gut^{11,43}, it is useful to evaluate whether a dietary supplementation could also stimulate the expression of the Aime-*DEFB139* gene in the digestive tract and thus improve the health of giant pandas in captivity, who tend to lack butyrate-producing bacteria³⁸. Another gene expressed in the blood, Aime-*DEFB103*, is also worth mentioning because it provides a non-destructive approach to the study of the adaptive evolution of giant pandas. The use of blood samples could help identify changes in Aime-*DEFB103* gene expression in different giant panda populations. Identification of a link between the gene expression and fitness in a population would aid in the selection of suitable individuals for breeding. Furthermore, the scope and depth of future studies could also be improved by including samples from different individuals, as our study focused on genes expressed in samples taken from one individual panda that died from acute haemorrhagic enteritis, which could have affected the expression of defensin genes. Because the acquisition of tissue samples from giant pandas is challenging, increased collaboration between different institutions will be needed in the future to conduct more comprehensive studies in this species.

Methods

Ethics statement. All the samples used in this study were collected with permission from the China Research and Conservation Center for the Giant Panda and the State Forestry Administration. The blood sample was collected from the arm vein of a male individual bred in the China Research and Conservation Center for the Giant Panda, and was obtained by the technical staff of the centre with utmost care. The centre also provided other preserved tissue samples, including the heart, kidney, liver, ovary, pancreas, spleen, stomach, and small and large intestines that were collected from an individual that had died of acute haemorrhagic enteritis. All experiments were approved by the ethics committees of the China Research and Conservation Center for the Giant Panda and were performed in accordance with the approved guidelines.

Search for new defensin genes in giant pandas. To identify potential novel β -defensins in the giant panda, initial TBLASTN searches were conducted on the nucleotide collection (nr/nt), reference genomic sequences (refseq_genomic), high-throughput genomics sequences (HTGS), and whole genome shotgun contigs (WGS) databases of the giant panda available at the National Center for Biotechnology Information (NCBI). These searches used all existing β -defensins in the giant panda together with orthologs exclusive to humans (*Homo sapiens*), mice (*Mus musculus*), cattle (*Bos taurus*), and dogs (*Canis lupus familiaris*) as query sequences. Hits with an E-value < 0.1 were examined manually for the typical motif or conserved signal sequence of β -defensin. For each potential newly identified gene, additional iterative searches were performed using the above method until no more sequences could be discovered. All searches used the default settings of the NCBI web site tools.

A hidden Markov model (HMM) analysis was used as a complementary strategy to search for novel β -defensins. Previously identified amino acid β -defensin sequences in the giant panda were aligned using ClustalW in MEGA 6.0 and trimmed to retain the core of the mature peptide where the conserved six-cysteine motif is located⁴⁴. The alignment was then submitted to the hmmsearch program on the HMMER web server to construct a HMM⁴⁵, which was then used to query the UniProt Knowledgebase (UniProtKB) using default settings. Potential hits were checked for the six-cysteine motif and additional iterative searches were performed as described above. Mammalian β -defensins have a signal sequence and mature peptide separated by an intron. Therefore, when a motif lacked a signal section or vice versa, a flanking sequence of 5–20 kb was retrieved to derive the full length and structural organisation of the gene by using a combination of SignalP⁴⁶, GENSCAN⁴⁷, Fgenesh⁴⁸, and GeneWise⁴⁹.

Because new defensin genes tend to arise through duplication and form clusters, the sequences between two neighbouring defensins were also retrieved and scanned using Genescan and Fgenesh to find distant homology. Moreover, assuming that closely related genes (bootstrap value above 55), including *DEFB103* and *DEFB2*, *DEFB109* and *DEFB130*, *DEFB116* and *DEFB116*-like, *DEFB126* and *DEFB126*-like, and *DEFB128* and *DEFB129*, could have other recent duplicates nearby, the gaps around these genes would be filled through PCR if larger than 120 bp because the mature β -defensin peptide has at least 40 amino acids. When a gap was too wide to be filled by PCR, we applied BAC walking based on our lab's panda BAC library to cover the gap¹⁷, and then used the identified clones as a template for amplification using universal primers for the flanking defensin genes. PCR products, if any, were sequenced and scanned using a combination of Genescan and Fgenesh to check for novel β -defensins. The primers used are listed in Supplementary Tables S8 and S9.

Evolutionary analyses. A phylogenetic tree of β -defensins in the giant panda, dog, cattle, mouse, and humans was reconstructed using MEGA 6.0. The program was employed to align the translated mRNA sequences (Supplementary Data S1 and S2) and then select the best substitution model to generate a neighbour-joining tree using the chicken DEFB1 as an outgroup. One thousand bootstrap replicates were performed to assess node support. Maximum likelihood trees were also constructed for both nucleotide and amino acid sequences using PhyML⁵⁰. As there was no significant difference in the clustering of the orthologs, these trees are not presented. In addition, the relative positions and orientations of all β -defensins from different species were investigated using BLAT⁵¹.

The expression of *DEFB1*, *DEFB103*, *DEFB139*, and *DEFB140* was detected in the giant panda; therefore, these four genes were chosen for further phylogenetic analyses. To better reflect their phylogeny, we included their orthologs, which were retrieved from NCBI (all accession numbers and sequences of the species included are in Supplementary Data S3 and S4). MEGA 6.0 was used to build phylogenetic trees with a maximum likelihood algorithm. Nucleotide sequences were aligned, and the best nucleotide substitution model was chosen for each alignment. A fast subtree-pruning-regrafting search using a weak branch swap filter was enforced on an initial maximum parsimony tree. One thousand bootstrap replicates were performed to assess node support.

For each gene, the overall mean rates of nonsynonymous (dN) and synonymous (dS) substitutions in the entire peptide and mature peptide domain, and the significance of the overall selection, were evaluated by Z-test of selection in MEGA 6.0 using a modified Nei and Gojobori method with the Jukes-Cantor correction, 1,000 bootstrap replicates, and a 90% site coverage cut-off. The overall selective pressure on the entire sequence and mature peptide domain were also measured using BUSTED on the datamonkey web server, which identified gene-wide evidence of episodic positive selection based on sites under periodic positive selection^{33,52}.

To examine the hypothesis that particular defensins in the giant panda have evolved under positive selection to handle changes in pathogenic exposure, we built branch models for the whole peptide and separately for the mature peptide region using the CodeML program in PAMLX to evaluate the dN/dS (ω) variation between different carnivore lineages and the rest of the tree⁵³. In each analysis, the null one-ratio model, which assigns the same ω to all branches, was compared with the alternative two-ratio model. The latter model estimates one ω for a single carnivore lineage treated as a foreground branch (i.e. tested lineage) and assigns another ω for the remaining branches (i.e. reference lineages). If the alternative model where the panda branch has a different ω is the best fit, we can infer that the panda β -defensin was under an evolutionary scheme different from that of other mammals. This analysis was followed by applying a Branch-Site Model in CodeML and MEME on the datamonkey web server to identify specific sites under positive selection³². MEME can also identify branches under periodic positive selection. RELAX, on the datamonkey web server, was used as a complementary analysis to determine whether selective pressure on the panda β -defensins had intensified during evolution³⁵ (detailed in Supplementary Methods).

Expression pattern of β **-defensins in the giant panda.** Total RNA from tissues isolated from the giant panda was extracted using phenol-chloroform and Trizol according to the manufacturer's instructions (Invitrogen, Carlsbad, CA). After the evaluation of RNA quality by agarose gel electrophoresis, cDNA was synthesized from 2–3 µg of RNA using the TAKARA Synthesis kit (Takara, Shiga, Japan, PrimeScript RT reagent Kit with gDNA Eraser) following the manufacturer's instructions. Primers spanning the intron were designed (Supplementary Table S10) for each giant panda β -defensin gene, and the expression patterns of these defensin genes were examined in each tissue.

Analysis of physiochemical properties and modelling of the Aime-DEFB139 mature peptide. The physiochemical parameters closely related to antimicrobial activities of AMPs, including isoelectric point and stability were calculated with the Isoelectric Point Calculator and ProtParam^{22,29-31,54,55}, respectively. To examine whether β -defensins from giant panda have distinctive physiochemical characteristics that may indicate a different antimicrobial activity from that of other carnivore β -defensins, the differences within the orthologs were tested using the Mahalanobis distance calculated using EXCEL 2007 (Microsoft Co., Ltd.), which is a popular method for detecting outliers in multivariate data⁵⁶. The Mahalanobis distance represents the distance from an observation to its prediction, where the observations are assumed to have a Gaussian distribution in the null hypothesis. If the null hypothesis is rejected, we can conclude that outliers from the Gaussian distribution exist. According to Penny (1996), the critical value for a small sample should be calculated as:

$$\frac{df_1 \times (df_2 - 1)^2 \times F_{df_1, df_2 - df_1 - 1; \alpha/df_2}}{df_2 \times \left(df_2 - df_1 - 1 + df_1 \times F_{df_1, df_2 - df_1 - 1; \alpha/df_2}\right)}$$
(1)

where df₁ is the number of parameters measured, df₂ refers to the number of observations for each parameter, and the significance level α is divided by df₂ to take multiple statistical tests into account (i.e. Bonferroni bounds)⁵⁶.

The tertiary structure of β -defensin proteins in the giant panda was also predicted. The giant panda sequences were subjected to the SWISS-MODEL to identify the most similar sequence to provide the basis for modelling the peptides' tertiary structure⁵⁷. The models were further analysed using Swiss-PdbViewer v4.10⁵⁸.

Antibacterial activity assay. To compare the antibacterial activities of the giant panda DEFB139 mature peptide and its respective Aime-DEFB139 peptide in which an Arg-to-Pro substitution was engineered, we chemically synthesized the two peptides. The two peptides, YRHGEVYHFC (Acm) DSRTSVC (Acm) LRRKRNC (Acm) LVRMRGVC (Acm) PGRSFC(Acm) C (Acm) IRMK (i.e. Aime-DEFB139) and YRHGEVYHFC (Acm) DSRTSVC (Acm) LRRKRNC (Acm) LVRMPGVC (Acm) PGRSFC (Acm) C (Acm) IRMK (i.e. Arg-to-Pro-substituted Aime-DEFB139), were synthesized through solid-phase peptide synthesis by the Chinese Peptide Company (Hangzhou, China). The same company purified all peptides by HPLC and verified their molecular weight by electrospray ionization mass spectrometric (ESI-MS). The detailed information of syntheses, purification, and characterizations were reserved by the company.

The two peptides were analyzed by CD spectroscopy using the Jasco J-1500 Circular Dichroism Spectrometer (JASCO, Inc., Easton, MD). The samples were prepared at 200 mg/L in sterile deionized water directly before measurement. CD measurements were performed at room temperature within a 180–280 nm wavelength range.

Every sample was scanned three times. The smoothed and averaged data were generated by the instrument's accompanying software and then analysed by using the CDPro software package⁵⁹.

The broth microdilution method described by Wiegand *et al.*⁶⁰ was used to evaluate the antimicrobial activities of the two antimicrobial peptides against *E. coli* ATCC25922, *S. aureus* ATCC25923, *Y. enterocolitica* CMCC52204, and *K. pneumoniae* ATCC 13883, which are pathogenic bacteria found in the intestinal tract of giant pandas. Each strain was diluted to approximately 5×10^5 CFU/mL in quarter-strength Mueller-Hinton broth (MH broth), and each peptide was prepared at 2560 mg/L in sterile deionized water. The individual peptides were then diluted in a continuous concentration gradient to 256, 128, 64, 32, 16, 8, 4, 2, 1, and 0.5 mg/L with 100 µL of quarter-strength MH broth in a 96-well cell culture plate (Costar 3599, Corning, Inc., Corning, NY). A 100 µL growth control containing no peptide and a 200-µL sterility control without inoculum were also included. Then, 100 µL of the diluted strain was mixed with 100 µL of the individual peptides at different concentrations, such that the final concentrations of the peptide in each well were 0–128 mg/L. The plates were incubated at 37 °C, and the turbidity at 600 nm at 8 h, 18 h and 24 h was measured using a microplate reader (SpectraMax 190, Molecular Devices, San Jose, CA). The survival percentage of bacteria was defined as the ratio of the turbidity in the wells with the peptide to that without the peptide. All experiments were performed in triplicate on two independent occasions. All values are expressed as the mean + standard deviation (SD).

We used Minitab 17 (Minitab Inc.) to conduct an analysis of variance (ANOVA) to determine whether a peptide has antimicrobial activity at different concentrations. Means were compared using Tukey's and Dunnett's tests. Significant differences in antimicrobial activity between the two peptides at a specific concentration were determined using the Student's t-test. Statistical significance was defined at p < 0.05.

Data availability. All data generated or analyzed during this study are included in this published article and its Supplementary Information files.

References

- 1. Jarczak, J. et al. Defensins: natural component of human innate immunity. Hum. Immunol. 74, 1069–1079 (2013).
- Patil, A. A., Hughes, A. L. & Zhang, G. Rapid evolution and diversification of mammalian α-defensins as revealed by comparative analysis of rodent and primate genes. *Physiol. Genomics* 20, 1–11 (2004).
- 3. Li, D. Y. *et al.* Evolution of primate alpha and theta defensins revealed by analysis of genomes. *Mol. Biol. Rep.* **41**, 3859–3866 (2014). 4. Patil, A. A., Cai, Y., Sang, Y., Blecha, F. & Zhang, G. L. Cross-species analysis of the mammalian beta-defensin gene family: presence
- of syntenic gene clusters and preferential expression in the male reproductive tract. Physiol. Genomics 23, 5-17 (2005).
- 5. Navid, F. *et al.* Induction of regulatory T cells by a murine β -defensin. *J. Immunol.* **188**, 735–743 (2012).
- Röhrl, J., Yang, D., Oppenheim, J. J. & Hehlgans, T. Human β-defensin 2 and 3 and their mouse orthologs induce chemotaxis through interaction with CCR2. J. Immunol. 184, 6688–6694 (2010).
- Hardwick, R. J. et al. A worldwide analysis of beta-defensin copy number variation suggests recent selection of a high-expressing DEFB103 gene copy in East Asia. Hum. Mutat. 32, 743–750 (2011).
- 8. Tollner, T. L. et al. A common mutation in DEFB126 causes impaired sperm function and subfertility. Sci. Transl. Med. 3, 92ra65–92ra65 (2011).
- Narciandi, F., Lloyd, A. T., Meade, K. G. & O'Farrelly, C. A novel subclass of bovine beta-defensins links reproduction and immunology. *Reprod. Fert. Develop.* 26, 769–777 (2014).
- Narciandi, F., Lloyd, A. T., Chapwanya, A., O'Farrelly, C. & Meade, K. G. Reproductive tissue-specific expression profiling and genetic variation across a 19 Gene bovine β-defensin cluster. *Immunogenetics*. 63, 641–651 (2011).
- 11. Sunkara, L. T. *et al.* Butyrate enhances disease resistance of chickens by inducing antimicrobial host defense peptide gene expression. *Plos One* **6**, e27225, https://doi.org/10.1371/journal.pone.0027225 (2011).
- Meade, K. G., Cormican, P., Narciandi, F., Lloyd, A. & Farrelly, C. Bovine β-defensin gene family: opportunities to improve animal health? *Physiol. Genomics.* 46, 17–28 (2014).
- 13. Wei, F. W. *et al.* Black and white and read all over: the past, present and future of giant panda genetics. *Mol. Ecol.* **21**, 5660–5674 (2012).
- Chen, Y. Y. et al. Natural selection coupled with intragenic recombination shapes diversity patterns in the major histocompatibility complex class II genes of the giant panda. J. Exp. Zool. (Mol. Dev. Evol.). 314B, 208–223 (2010).
- Chen, Y. Y. et al. Patterns of adaptive and neutral diversity identify the Xiaoxiangling mountains as a refuge for the giant panda. Plos One 8, e70229, https://doi.org/10.1371/journal.pone.0070229 (2013).
- 16. Zhu, Y. *et al.* Isolation and characterization of class I MHC genes in the giant panda (*Ailuropoda melanoleuca*). *Chinese Sci. Bull.* **58**, 2140–2147 (2013).
- 17. Zeng, C. J. *et al.* Giant panda BAC library construction and assembly of a 650-kb contig spanning major histocompatibility complex class II region. *BMC Genomics* **8**, 315 (2007).
- 18. Wei, F. W., Wang, X. & Qi, W. The giant panda gut microbiome. Trends Microbiol. 23, 450-452 (2015).
- 19. Cheng, Y. Y. *et al.* Evolution of the avian β -defensin and cathelicidin genes. *BMC Evol. Biol.* **15**, 188 (2015).
- Guruprasad, K., Reddy, B. V. B. & Pandit, M. W. Correlation between stability of a protein and its dipeptide composition: a novel approach for predicting *in vivo* stability of a protein from its primary sequence. *Protein Eng.* 4, 155–161 (1990).
- Dhople, V., Krukemeyer, A. & Ramamoorthy, A. The human beta-defensin-3, an antibacterial peptide with multiple biological functions. *Biochi. Biophy. Acta* 1758, 1499–1512 (2006).
- Klüver, E., Adermann, K. & Schulz, A. Synthesis and structure–activity relationship of β-defensins, multi-functional peptides of the immune system. J. Pept. Sci. 12, 243–257 (2006).
- 23. Yeaman, M. R. & Yount, N. Y. Mechanisms of antimicrobial peptide action and resistance. Pharmacol Rev. 55, 27-55 (2003).
- 24. Wu, Z. B. *et al.* Engineering disulfide bridges to dissect antimicrobial and chemotactic activities of human β-defensin 3. *PNAS* **100**, 8880–8885 (2003).
- Sun, Z. Y., Wu, S. & Wang, S. Q. Application of liquid chromatography-electrospray ionization mass spectrometry in protein sequencing. *Basic Clin. Med.* 23, 126–131 (2003).
- 26. Nei, M. & Rooney, A. P. Concerted and birth-and-death evolution of multigene families. Annu. Rev. Genet. 39, 121–152 (2005).
- 27. Li, Y.D. *et al.* The rapid evolution of signal peptides is mainly caused by relaxed selection on non-synonymous and synonymous sites. *Gene* **436**, 8–11.
- Semple, C. A. M. *et al.* The complexity of selection at the major primate β-defensin locus. *BMC Evol. Biol.* 5, 32, https://doi. org/10.1186/1471-2148-5-32 (2005).
- Papanastasiou, E. A. et al. Role of acetylation and charge in antimicrobial peptides based on human β-Defensin-3. Acta Path. Micro. Im. 117, 492–499 (2009).

- Huang, X. X., Gao, C. Y., Zhao, Q. J. & Li, Cl Antimicrobial characterization of site-directed mutagenesis of porcine beta-defensin 2. Plos One 10, e0118170, https://doi.org/10.1371/journal.pone.0118170 (2015).
- Chou, H. T. et al. Design and synthesis of cationic antimicrobial peptides with improved activity and selectivity against Vibrio spp. Int. J. Antimicrob. Agents 32, 130–138 (2008).
- Murrell, B. et al. Detecting individual sites subject to episodic diversifying selection. Plos Genet. 8, e1002764, https://doi.org/10.1371/ journal.pgen.1002764 (2012).
- Pond, S. L. K. et al. A random effects branch-site model for detecting episodic diversifying selection. Mol. Biol. Evo. 28, 3033–3043 (2011).
- Wertheim, J. O., Murrell, B., Smith, M. D., Pond, S. L. K. & Scheffler, K. RELAX: detecting relaxed selection in a phylogenetic framework. *Mol. Biol. Evol.* 32, 820–832 (2014).
- 35. Murrell, B. et al. Gene-wide identification of episodic selection. Mol. Biol. Evol. 32, 1365–1371 (2015).
- 36. Tu, J. B. et al. Molecular evolutionary analysis of beta-defensin peptides in vertebrates. Evol. Bioinform. 11, 105–114 (2015).
- 37. Chen, H. *et al.* Genomic structure and evolution of beta-defensin genes in the golden pheasant and hwamei. *Sci. Bull.* **60**, 679–690 (2015).
- Vital, M., Gao, J., Rizzo, M., Harrison, T. & Tiedje, J. M. Diet is a major factor governing the fecal butyrate-producing community structure across mammalia, aves and reptilia. *ISME J.* 9, 832–843 (2015).
- 39. Jin, C. et al. The first skull of the earliest giant panda. P. Nati. Acad. Sci. USA 104, 10932-10937 (2007).
- 40. Xiao, Y. *et al.* A genome-wide screen identifies a single beta-defensin gene cluster in the chicken: implications for the origin and evolution of mammalian defensins. *BMC Genomics* 5, 56, https://doi.org/10.1186/1471-2164-5-56 (2004).
- Hoover, D. M. *et al.* The structure of human β-defensin-2 shows evidence of higher order oligomerization. *J. Biol. Chem.* 275, 32911–32918 (2000).
- 42. Schibli, D. J. et al. The solution structures of the human-defensins lead to a better understanding of the potent bactericidal activity of HBD3 against *Staphylococcus aureus*. J. Biol. Chem. 277, 8279–8289 (2002).
- 43. Zasloff, M. Inducing endogenous antimicrobial peptides to battle infections. P. Nati. Acad. Sci. USA 103, 8913-8914 (2006).
- Tamura, K., Stecher, G., Peterson, D., Filipski, A. & Kumar, S. MEGA6: molecular evolutionary genetics analysis version 6.0. *Mol. Biol. Evol.* 30, 2725–2729 (2013).
- Finn, R. D., Clements, J. & Eddy, S. R. HMMER web server: interactive sequence similarity searching. Nucleic Acids Res. 39, W29–W37, https://doi.org/10.1093/nar/gkr367 (2011).
- Petersen, T. N., Brunak, S., Heijne, G. V. & Nielsen, H. SignalP 4.0: discriminating signal peptides from transmembrane regions. *Nat. Methods* 8, 785–786 (2011).
- 47. Burge, C. & Karlin, S. Prediction of complete gene structures in human genomic DNA. J. Mol. Bio. 268, 78-94 (1997).
- Solovyev, V., Kosarev, P., Seledsov, I. & Vorobyev, D. Automatic annotation of eukaryotic genes, pseudogenes and promoters. Genome Biol. 7, S10, https://doi.org/10.1186/gb-2006-7-s1-s10 (2006).
- 49. Birney, E. & Durbin, R. Using GeneWise in the Drosophila annotation experiment. Genome Res. 10, 547-548 (2000).
- Guindon, S. *et al.* New algorithms and methods to estimate maximum-likelihood phylogenies: assessing the performance of PhyML 3.0. Syst. Biol. 59, 307–321 (2010).
- 51. Kent, W. J. BLAT-the BLAST-like alignment tool. Genome Res. 12, 656-664 (2002).
- Delport, W., Poon, A. F. Y., Frost, S. D. W. & Pond, S. L. K. Datamonkey 2010: a suite of phylogenetic analysis tools for evolutionary biology. *Bioinformatics* 26, 2455–2457 (2010).
- 53. Xu, B. & Yang, Z. H. PAMLX: a graphical user interface for PAML. Mol. Biol. Evol. 30, 2723-2724 (2013).
- 54. Kozlowski, L. P. IPC-isoelectric point calculator. Biol. Direct. 11, 55, https://doi.org/10.1186/s13062-016-0159-9 (2016).
- 55. Gasteiger, E. et al. Protein identification and analysis tools on the ExPASy server in *The proteomics protocols handbook* (ed. Walke, J. M.) 571–607 (Humana Press, 2005).
- 56. Penny, K. I. Appropriate critical values when testing for a single multivariate outlier by using the Mahalanobis distance. J. Roy. Stat. Soc. C-App. 45, 73–81 (1996).
- Biasini, M. et al. SWISS-MODEL: modelling protein tertiary and quaternary structure using evolutionary information. Nucleic Acids Res. 42, W252–W258, https://doi.org/10.1093/nar/gku340 (2014).
- Guex, N. & Peitsch, M. C. SWISS-MODEL and the Swiss-PdbViewer: an environment for comparative protein modelling. Electrophoresis 18, 2714–2723 (1997).
- Sreerama, N. & Woody, R. W. Estimation of protein secondary structure from CD spectra: comparison of CONTIN, SELCON and CDSSTR methods with an expanded reference set. *Anal. Biochem* 287, 252–260 (2000).
- Wiegand, I., Hilpert, K. & Hancock, R. E. W. Agar and broth dilution methods to determine the minimal inhibitory concentration (MIC) of antimicrobial substances. *Nature Proto.* 3, 163–175 (2008).

Acknowledgements

We would like to thank the China Research and Conservation Center for the Giant Panda for providing tissue samples. This work was supported by a National Key Program (2016YFC0503200) from the Ministry of Science and Technology of China, a special grant for the giant panda from the State Forestry Administration of the People's Republic of China, and the Fundamental Research Funds for the Central Universities of the People's Republic of China.

Author Contributions

S.G.F. conceived and designed the research. Z.Y.Z. conducted the research and drafted an earlier version of this manuscript which was later revised by S.G.F. and Z.Y.Z. Reagents, samples and analysis tools were provided by H.M.Z., D.S.L and T.Y.X. All authors read and approved the final manuscript.

Additional Information

Supplementary information accompanies this paper at https://doi.org/10.1038/s41598-018-29898-2.

Competing Interests: The authors declare no competing interests.

Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2018